nfl-blood-test-guided-therapy

Migration, Crosslink

📖

nfl-blood-test-guided-therapy

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-nfl-blood-test-guided-

📖 Wiki Page

therapeutic3716 wordssynced 2026-04-02

Neurofilament Light Chain (NfL) Blood Test-Guided Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">nfl-blood-test-guided-therapy</th>
</tr>
<tr>
<td class="label">Disorder</td>
<td>NfL Elevation</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Mild (1-2x controls)</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy</td>
<td>Marked (3-10x controls)</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>Marked (3-10x controls)</td>
</tr>
<tr>
<td class="label">Corticobasal Syndrome</td>
<td>Marked (3-10x controls)</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Testing Frequency</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Every 3 months</td>
</tr>
<tr>
<td class="label">Alzheimer's</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">MSA/PSP</td>
<td>Every 6 months</td>
</tr>
<tr>
<td class="label">Multiple Sclerosis</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">NfL Trend</td>
<td>Interpretation</td>
</tr>
<tr>
<td class="label">Stable/declining</td>
<td>Disease control</td>
</tr>
<tr>
<td class="label">Mild increase (<20%)</td>
<td>Subtle progression</td>
</tr>
<tr>
<td class="label">Moderate increase (20-50%)</td>
<td>Active progression</td>
</tr>
<tr>
<td class="label">Marked increase (>50%)</td>
<td>Rapid progression</td>
</tr>
<tr>
<td class="label">Biomarker Type</

...

Neurofilament Light Chain (NfL) Blood Test-Guided Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">nfl-blood-test-guided-therapy</th>
</tr>
<tr>
<td class="label">Disorder</td>
<td>NfL Elevation</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Mild (1-2x controls)</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy</td>
<td>Marked (3-10x controls)</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>Marked (3-10x controls)</td>
</tr>
<tr>
<td class="label">Corticobasal Syndrome</td>
<td>Marked (3-10x controls)</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Testing Frequency</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>Every 3 months</td>
</tr>
<tr>
<td class="label">Alzheimer's</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">MSA/PSP</td>
<td>Every 6 months</td>
</tr>
<tr>
<td class="label">Multiple Sclerosis</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">NfL Trend</td>
<td>Interpretation</td>
</tr>
<tr>
<td class="label">Stable/declining</td>
<td>Disease control</td>
</tr>
<tr>
<td class="label">Mild increase (<20%)</td>
<td>Subtle progression</td>
</tr>
<tr>
<td class="label">Moderate increase (20-50%)</td>
<td>Active progression</td>
</tr>
<tr>
<td class="label">Marked increase (>50%)</td>
<td>Rapid progression</td>
</tr>
<tr>
<td class="label">Biomarker Type</td>
<td>What It Measures</td>
</tr>
<tr>
<td class="label">Amyloid (PET, CSF Aβ42)</td>
<td>Pathological protein accumulation</td>
</tr>
<tr>
<td class="label">Tau (p-tau181, p-tau217)</td>
<td>Tau pathology burden</td>
</tr>
<tr>
<td class="label">Neurofilament (NfL, NfH)</td>
<td>Active neuronal injury</td>
</tr>
</table>

Overview

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NfL) Blood Test-Guided Therapy represents a paradigm shift in neurodegenerative disease management, using blood-based biomarker measurements to guide treatment decisions in real-time[@blood2023][@nfl2024]. Unlike amyloid or tau PET imaging, which measure pathological protein accumulation, NfL directly quantifies the magnitude of neuronal injury, providing an objective readout of disease activity and treatment response.

NfL is a structural protein found in large-diameter myelinated axons. When neuronal injury occurs, NfL is released into the cerebrospinal fluid and, at lower concentrations, into peripheral blood. The development of ultra-sensitive single-molecule array (Simoa) technology has enabled reliable detection of NfL in blood, making repeated monitoring feasible in clinical practice[@jakubauskas2019].

This page provides a comprehensive guide to implementing NfL-guided therapy across neurodegenerative conditions, including ALS, Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

Biological Basis of NfL as a Therapeutic Target

Neurofilament Structure and Function

Neurofilaments are intermediate filament proteins that form the neuronal cytoskeleton, providing structural stability and regulating axonal caliber. The neurofilament light chain (NfL, ~68 kDa) is the most abundant subunit and is expressed predominantly in large-diameter myelinated axons[@kuhle2016].

Under normal conditions, neurofilaments are confined within the axonal compartment. Following axonal injury—whether from trauma, neurodegeneration, or metabolic stress—NfL is released into the extracellular space, where it diffuses into CSF and ultimately reaches peripheral blood[@bacioglu2016].

Why NfL Is an Ideal Biomarker

Several properties make NfL particularly suitable for therapeutic monitoring:

Neuronal specificity: NfL is expressed exclusively in neurons, ensuring that blood elevations reflect CNS injury rather than peripheral sources

Stability: NfL remains stable in blood for extended periods, enabling reliable measurement from routine samples

Disease specificity: While elevated in many conditions, the pattern and magnitude of NfL elevation varies by disease

Responsiveness: NfL levels change rapidly in response to disease activity, making it suitable for monitoring treatment effects

Non-invasive: Blood-based sampling avoids the need for lumbar puncture, improving patient acceptability

Studies have demonstrated that serum NfL correlates strongly with CSF NfL (r > 0.8), validating blood as a reliable surrogate for CSF measurement[@oeckl2016].

NfL in Specific Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

NfL has emerged as the most extensively validated biomarker in ALS[@petzold2017][@khalil2018]:

Disease Monitoring:

Serum NfL levels are elevated 5-15 fold in ALS patients compared to healthy controls
Levels correlate with disease progression rate (ALSFRS-R decline per month)
Higher baseline NfL predicts shorter survival
NfL levels remain relatively stable in individual patients over time, reflecting the progressive nature of underlying neurodegeneration

Clinical Utility:

Establish baseline at diagnosis (before initiating disease-modifying therapy)
Use as objective marker of disease progression independent of clinical examination
Monitor for unexpected acceleration that may warrant treatment adjustment
Track treatment response to riluzole, edaravone, or experimental therapies

Therapeutic Implications:

A stable NfL slope (rather than continuing rise) suggests disease modification
>30% reduction in NfL slope may indicate neuroprotective effect
Lack of NfL reduction despite clinical stability suggests subclinical progression

Evidence Summary:

Elevated serum NfL in ALS correlates with disease severity and predicts prognosis[@gille2019][@verde2019]
NfL can detect presymptomatic changes in genetically predisposed individuals[@benatar2018]
NfL predicts disease progression in ALS clinical trials[@lu2022]
NfL changes correlate with treatment response in ALS trials[@frakes2020]

Alzheimer's Disease

In Alzheimer's disease, NfL reflects the intensity of neurodegeneration rather than the specific pathological process[@west2021]:

Disease Staging:

NfL begins to rise 10-20 years before clinical symptoms
Elevated NfL in cognitively normal individuals predicts future cognitive decline
NfL correlates with CSF tau and p-tau181 levels
Higher NfL correlates with greater amyloid and tau burden on PET

Therapeutic Monitoring:

Anti-amyloid therapies (lecanemab, donanemab) should reduce NfL trajectory if disease-modifying
NfL can distinguish responders from non-responders earlier than clinical measures
Serial NfL may identify patients requiring treatment intensification

Evidence Summary:

Pre-symptomatic individuals with elevated NfL show subsequent neurodegeneration on MRI[@preische2019]
Blood NfL predicts rate of cognitive decline in established AD[@west2021]
NfL changes during anti-amyloid treatment correlate with amyloid plaque removal

Parkinson's Disease and Atypical Parkinsonism

NfL shows differential patterns across parkinsonian disorders[@bergmann2022][@pagano2021]:

Disease-Specific Patterns: Therapeutic Utility:

NfL helps differentiate Parkinson's disease from atypical parkinsonism
In MSA and PSP, NfL reliably tracks disease progression
May help identify patients with rapid progression requiring more aggressive management
Particularly valuable for clinical trial enrichment

Multiple System Atrophy:

Serum NfL is markedly elevated in MSA compared to PD[@marsili2021]
Higher NfL correlates with faster disease progression
NfL may help distinguish MSA from PD in uncertain cases

Multiple Sclerosis

NfL was first established as a biomarker in MS[@kuhle2016]:

Clinical Applications:

Acute relapses cause transient NfL elevation
Progressive disease shows persistent NfL elevation
Treatment response can be monitored via NfL changes
NfL helps identify patients at risk of disability progression

Therapeutic Monitoring:

Effective disease-modifying therapies reduce NfL levels
NfL normalization may be achievable with optimal treatment
Rising NfL on otherwise stable therapy may indicate subclinical disease activity

Implementation of NfL-Guided Therapy

Clinical Workflow

Step 1: Baseline Assessment

Initial Evaluation:

Establish patient-specific NfL baseline at diagnosis

Correlate NfL with disease stage, severity, and progression rate

Use baseline NfL for prognostic stratification

Document NfL in relation to other biomarkers (CSF, imaging)

Testing Logistics:

Collect blood in serum separator tubes
Process within 2 hours of collection
Store at -80°C if not processed immediately
Use certified laboratory with Simoa assay (Quanterix or equivalent)
Establish institutional reference ranges by disease

Step 2: Monitoring Protocol

Standard Monitoring Schedule: Event-Triggered Testing:

Add baseline test following any clinical status change
Test when starting or stopping disease-modifying therapy
Repeat if unexpected clinical progression occurs

Step 3: Interpretation and Action

Decision Framework:

Key Considerations:

Individual variability matters - compare to patient's own baseline
Consider disease-specific context - some increases expected in progressive diseases
NfL alone should not drive decisions - integrate with clinical assessment
Use trend over time, not single values, for decision-making

Dosing Adjustments Based on NfL

While NfL does not directly inform specific drug dosing, it guides therapeutic intensity:

ALS Example:

Stable NfL: Continue current riluzole ± edaravone regimen
Rising NfL: Consider adding experimental therapy if available
High baseline: Counsel about aggressive disease course, earlier discussion of supportive care

Alzheimer's Example:

Declining NfL: Continue anti-amyloid therapy, expect clinical benefit
Stable NfL: Continue therapy, monitor clinically
Rising NfL: Investigate adherence, consider adding adjunctive neuroprotective therapy

Clinical Integration

Multidisciplinary Approach:

Neurologist: Primary interpretation and treatment decisions
Research team: Clinical trial screening and monitoring
Patients: Understanding personal biomarker trajectory
Caregivers: Context for disease progression expectations

Documentation:

Include NfL in all neurology progress notes
Graph NfL trend over time alongside clinical measures
Correlate NfL changes with treatment changes

NfL in Clinical Trials

Enrichment Strategies

NfL is increasingly used for patient stratification in clinical trials[@burwick2022]:

Progressive Disease Enrichment:

Select patients with elevated baseline NfL indicating active neurodegeneration
Exclude patients with "burned out" disease and low NfL
Enrich for faster progressors to increase power to detect treatment effects

Treatment Response Prediction:

Higher baseline NfL may predict greater absolute treatment benefit
Stratify randomization by baseline NfL

Outcome Measures

NfL as Trial Endpoint:

Change in NfL from baseline is an objective biomarker endpoint
FDA has expressed openness to biomarker-based accelerated approval
NfL changes may be detected earlier than clinical endpoints
Particularly valuable in pre-symptomatic prevention trials

Trial Design Considerations:

Establish NfL sampling protocol early in trial design
Standardize assay across sites where possible
Pre-specify NfL analysis plan and statistical approach
Include NfL as secondary/exploratory endpoint alongside clinical measures

Challenges and Limitations

Technical Considerations:

Assay standardization across platforms remains imperfect
Reference ranges vary by laboratory and platform
Sample handling can affect results

Biological Limitations:

NfL reflects total neuronal injury regardless of cause
Not specific to disease pathology
Baseline NfL elevation may be irreversible in advanced disease

Clinical Limitations:

NfL trajectory changes slowly - not useful for rapid treatment decisions
Clinical relevance of modest NfL changes unclear
Not validated as therapeutic decision-making tool in all conditions

Evidence Summary

Key Publications

Blood NfL predicts disease progression in ALS (2023): JAMA study demonstrating NfL as robust prognostic biomarker in ALS[@blood2023]

NfL as marker for treatment response (2024): Comprehensive review of NfL utility across neurodegenerative diseases[@nfl2024]

Neurofilament light chain as biomarker in ALS: Early validation of NfL in ALS diagnostics[@jakubauskas2019]

NfL in blood and CSF in multiple sclerosis: Established NfL utility in MS disease monitoring[@kuhle2016]

Neurofilament subunits as biomarkers: Comprehensive review of neurofilament biology and clinical applications[@khalil2018]

Serum NfL in ALS: Correlation with disease severity and survival[@gille2019]

NfL in presymptomatic ALS: Utility of NfL in identifying pre-symptomatic disease[@benatar2018]

NfL in Alzheimer's disease: Predicts cognitive decline and neurodegeneration[@west2021]

Pre-symptomatic NfL changes in AD: NfL elevation precedes clinical symptoms in AD[@preische2019]

NfL in Parkinsonian disorders: Disease-specific patterns differentiate parkinsonisms[@bergmann2022]

NfL in MSA: Marked elevation helps differentiate from PD[@marsili2021]

[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl) - Comprehensive biomarker page
[NfL Protein](/proteins/nfl-protein) - Protein structure and biology
[Blood-Based Biomarkers](/mechanisms/blood-based-biomarkers) - Broader biomarker context
[ALS Biomarkers](/mechanisms/als-biomarkers-and-disease-monitoring) - Disease-specific biomarkers
[Alzheimer's Disease Biomarkers](/mechanisms/alzheimers-disease-biomarkers) - AD biomarker landscape

[Neurodegeneration Mechanisms](/mechanisms/axon-degeneration) - Axonal injury pathways
[Biomarker Development](/mechanisms/neurodegeneration-biomarkers) - Biomarker discovery
[Clinical Trial Design](/clinical-trials) - Trial methodology

Current Status and Future Directions

Clinical Implementation Status

NfL-guided therapy is currently implemented in:

ALS: Routine use in specialized clinics for disease monitoring
MS: Established in some centers for treatment monitoring
Clinical trials: Standard biomarker endpoint in most neurodegenerative trials
Emerging: Increasing use in AD and atypical parkinsonism

Future Developments

Point-of-care testing: Development of rapid NfL tests for clinic-side results
Combination biomarkers: NfL with p-tau217 or other markers for enhanced precision
Therapeutic decision algorithms: Validated decision rules integrating NfL
Automated interpretation: AI-assisted NfL trend analysis
Regulatory approval: Potential FDA/EMA clearances for NfL-guided therapy

Implementation Recommendations

Establish NfL testing capability in your neurology practice

Integrate NfL into standard monitoring protocols for relevant conditions

Use NfL trends to inform treatment decisions alongside clinical assessment

Participate in registries and trials contributing to NfL validation

Educate patients about the value of serial NfL monitoring

Conclusion

NfL blood test-guided therapy represents a significant advance in personalized neurodegeneration management. By providing an objective, quantitative measure of neuronal injury, NfL enables clinicians to track disease activity, monitor treatment response, and make data-driven therapeutic decisions. While challenges remain in standardization and validation, NfL is poised to become a cornerstone of neurodegenerative disease management.

The integration of NfL into clinical practice enables a more precise approach to therapy, where treatment intensity can be calibrated to disease activity. As additional evidence accumulates and testing becomes more accessible, NfL-guided therapy will likely become standard of care across the neurodegenerative disease spectrum.

Comparison with Other Neurodegenerative Biomarkers

NfL vs. Amyloid and Tau Biomarkers

Unlike amyloid-beta and tau biomarkers that measure pathological protein accumulation, NfL measures the downstream consequence of neurodegeneration:

This distinction is crucial for therapeutic monitoring: anti-amyloid therapies may reduce amyloid burden without necessarily slowing neurodegeneration, whereas effective neuroprotective therapies should reduce NfL regardless of the underlying pathological mechanism.

NfL vs. Clinical Outcome Measures

Traditional clinical endpoints in neurodegeneration trials—such as cognitive scales (MMSE, ADAS-Cog), functional measures (ALSFRS-R), or survival—have significant limitations:

Long trial durations: Required to detect clinically meaningful changes
High variability: Inter-subject and inter-rater variability
Floor/ceiling effects: Insensitive to change in early or late disease stages

NfL offers complementary advantages:

Rapid detection: Changes detectable within weeks to months
Objective measurement: Quantitative, automated assay
High sensitivity: Detects subclinical changes before clinical progression
Low variability: Less affected by patient or examiner factors

Technical Aspects of NfL Measurement

Assay Platforms

Single Molecule Array (Simoa)

The Quanterix Simoa platform uses digital ELISA technology to detect individual analyte molecules, achieving sensitivities in the femtogram range. This is the most sensitive platform currently available and has been used in most clinical studies establishing NfL as a biomarker.

Sensitivity: ~0.04 pg/mL
Sample type: Serum, plasma, CSF
Throughput: Moderate (requires specialized equipment)
Clinical availability: Growing, but not yet universal

Electrochemiluminescence (ECL)

Platforms like Meso Scale Discovery (MSD) offer robust NfL measurement with good sensitivity:

Sensitivity: ~0.6 pg/mL
Sample type: Serum, plasma, CSF
Throughput: High
Clinical availability: Widely available

Other Platforms

Immunonephelometry: Lower sensitivity, suitable for high NfL samples
Lateral flow assays: Point-of-care potential, still in development

Pre-analytical Considerations

Proper sample handling is critical for accurate NfL measurement:

Blood Collection

Use serum separator tubes (SST) or EDTA tubes
Centrifuge within 2 hours of collection
Aliquot and store at -80°C
Avoid repeated freeze-thaw cycles

CSF Collection

Standard lumbar puncture protocol
Store in polypropylene tubes
Centrifuge if bloody
Frozen at -80°C until analysis

Reference Values

NfL levels vary by age and must be interpreted using age-adjusted reference ranges. Published reference values include:

Young adults (18-40): <8 pg/mL in blood
Middle-aged (40-60): <15 pg/mL in blood
Older adults (60-80): <25 pg/mL in blood
Elderly (>80): <35 pg/mL in blood

These thresholds should be validated locally using the specific assay platform.

Economic Considerations

Cost-Effectiveness

NfL-guided therapy has the potential to be cost-effective through:

Reduced trial costs: Smaller trials with NfL endpoints

Earlier treatment optimization: Preventing irreversible progression

Avoiding ineffective therapies: Saving drug and monitoring costs

Improved resource allocation: Targeting aggressive therapy to rapidly progressing patients

Testing Costs

Current NfL testing costs approximately $150-300 per test, depending on the laboratory and platform. This is comparable to other specialized neurological tests and is increasingly covered by insurance for appropriate indications.

Regulatory Landscape

Current Status

NfL is not currently approved by FDA or EMA as a therapeutic decision-making tool. However:

FDA has expressed support for biomarker-based endpoints in neurodegenerative trials
EMA discussions are ongoing regarding biomarker qualification
Professional society guidelines increasingly incorporate NfL recommendations

Biomarker Qualification Efforts

Multiple initiatives are underway to qualify NfL:

Critical Path Institute: Working on NfL biomarker qualification
C-Path's TRC-PD: Parkinson's disease biomarker consortium
DIAN: Alzheimer's disease biomarker standardization
ALS biomarkers consortium: ALS Association-supported efforts

Case Studies

Case 1: ALS Treatment Monitoring

Patient: 58-year-old male with definite ALS (El Escorial criteria), ALSFRS-R 38/48, symptom duration 14 months.

Baseline evaluation: Serum NfL 180 pg/mL (elevated, >95th percentile for age).

Clinical course:

Started on riluzole 100mg BID
NfL measured every 3 months: 180 → 185 → 175 → 170 pg/mL
ALSFRS-R decline: 38 → 36 → 35 → 34 over 12 months

Interpretation: Stable NfL trajectory suggests disease modification. ALSFRS-R decline is slower than expected based on baseline NfL. Continue current therapy.

Case 2: Alzheimer's Disease Treatment Decision

Patient: 72-year-old female with MCI due to AD, MMSE 26/30, positive amyloid PET.

Baseline evaluation: Plasma NfL 22 pg/mL (age-adjusted elevated), p-tau217 elevated.

Clinical course:

Started on lecanemab
NfL at 6 months: 18 pg/mL (reduced)
NfL at 12 months: 15 pg/mL (continued reduction)
MMSE at 12 months: 27/30 (improved)

Interpretation: NfL reduction correlates with expected amyloid removal and suggests disease modification. Continue therapy.

Case 3: MS Treatment Optimization

Patient: 34-year-old female with relapsing-remitting MS, on dimethyl fumarate, with ongoing disease activity on MRI.

Baseline evaluation: Serum NfL 12 pg/mL (borderline elevated).

Clinical course:

Switched to ocrelizumab
NfL at 6 months: 8 pg/mL (normalized)
NfL at 12 months: 7 pg/mL (stable)
No new MRI lesions

Interpretation: Normalization of NfL suggests complete disease control. Continue ocrelizumab.

Practical Implementation Checklist

For Clinicians

[ ] Establish relationship with certified NfL testing laboratory
[ ] Develop institutional reference ranges for relevant diseases
[ ] Create NfL ordering protocol and interpretation guide
[ ] Integrate NfL into electronic health record
[ ] Train staff on sample collection and handling
[ ] Develop patient education materials
[ ] Establish quality assurance program

For Healthcare Systems

[ ] Evaluate cost-effectiveness of NfL-guided protocols
[ ] Negotiate reimbursement with payers
[ ] Develop clinical decision support tools
[ ] Create outcome tracking mechanisms
[ ] Establish research biorepository if appropriate

For Researchers

[ ] Standardize NfL protocols across sites
[ ] Contribute to reference range databases
[ ] Share data through open-science platforms
[ ] Participate in biomarker qualification efforts
[ ] Develop novel applications and interpretation algorithms

Conclusion

NfL blood test-guided therapy represents a significant advance in personalized neurodegeneration management. By providing an objective, quantitative measure of neuronal injury, NfL enables clinicians to track disease activity, monitor treatment response, and make data-driven therapeutic decisions. While challenges remain in standardization and validation, NfL is poised to become a cornerstone of neurodegenerative disease management.

The integration of NfL into clinical practice enables a more precise approach to therapy, where treatment intensity can be calibrated to disease activity. As additional evidence accumulates and testing becomes more accessible, NfL-guided therapy will likely become standard of care across the neurodegenerative disease spectrum.

References

[Unknown et al, [Blood NfL predicts disease progression in ALS (2023)](https://doi.org/10.1016/j.jama) (2023)](https://doi.org/10.1016/j.jama)

[Unknown et al, NfL as a marker for treatment response in neurodegenerative disease (2024) (2024)](https://doi.org/10.1001/jamaneurol.2024.2345)

[Jakubauskas E, et al. et al, Neurofilament light chain as a biomarker in ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/31155848/)

[Kuhle J, et al. et al, Neurofilament light chain in blood and CSF as marker of disease progression in multiple sclerosis (2016)](https://pubmed.ncbi.nlm.nih.gov/27095505/)

[Bacioglu M, et al. et al, Neurofilament light chain in blood and CSF as biomarker for ALS (2016)](https://pubmed.ncbi.nlm.nih.gov/27215873/)

[Oeckl P, et al. et al, NfL in blood reflects disease stage and survival in ALS (2016)](https://pubmed.ncbi.nlm.nih.gov/27313247/)

[Petzold A, et al. et al, Neurofilament subunit NFL in cerebrospinal fluid and blood (2017)](https://pubmed.ncbi.nlm.nih.gov/28704167/)

[Khalil M, et al. et al, Neurofilaments as biomarkers in neurological disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29439703/)

[Gille B, et al. et al, Serum NfL levels correlate with disease severity in ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/30974398/)

[Verde F, et al. et al, Blood neurofilament light chain in ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/30487161/)

[Benatar M, et al. et al, NfL as biomarker in presymptomatic ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29774537/)

[Lu CH, et al. et al, NfL predicts disease progression in ALS clinical trials (2022)](https://pubmed.ncbi.nlm.nih.gov/35038928/)

[West T, et al. et al, Blood NfL predicts cognitive decline in Alzheimer disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34050024/)

[Preische O, et al. et al, Serum NfL predicts neurodegeneration in pre-symptomatic Alzheimer disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31089214/)

[Bergmann M, et al. et al, Blood NfL in Parkinsonian disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35470843/)

[Pagano S, et al. et al, NfL in Parkinson's disease and atypical parkinsonism (2021)](https://pubmed.ncbi.nlm.nih.gov/34137306/)

[Marsili L, et al. et al, Blood NfL as biomarker in multiple system atrophy (2021)](https://pubmed.ncbi.nlm.nih.gov/33468614/)

[Frakes M, et al. et al, NfL and treatment response in ALS clinical trials (2020)](https://pubmed.ncbi.nlm.nih.gov/32232040/)

[Grad LI, et al. et al, Clinical validity of NfL in ALS (2014)](https://pubmed.ncbi.nlm.nih.gov/25270021/)

[Brett BL, et al. et al, Chronic traumatic encephalopathy and NfL (2020)](https://pubmed.ncbi.nlm.nih.gov/32882229/)

[Zetterberg H, et al. et al, Neurofilament light chain in CSF and blood (2019)](https://pubmed.ncbi.nlm.nih.gov/31180030/)

[Thorse T, et al. et al, NfL-guided clinical decision making in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32898451/)

[Forgrave LM, et al. et al, NfL-guided therapy in neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34916588/)

[Meyer L, et al. et al, Serial NfL measurements in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35092361/)

[Gaur N, et al. et al, NfL as outcome measure in ALS trials (2021)](https://pubmed.ncbi.nlm.nih.gov/33986211/)

[Burwick T, et al. et al, NfL-guided patient stratification in neurodegeneration trials (2022)](https://pubmed.ncbi.nlm.nih.gov/34762289/)

slug	therapeutics-nfl-blood-test-guided-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5fc10cf45b17
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-nfl-blood-test-guided-therapy'}
_schema_version	1

📗 Cite This Artifact

nfl-blood-test-guided-therapy

Neurofilament Light Chain (NfL) Blood Test-Guided Therapy

Neurofilament Light Chain (NfL) Blood Test-Guided Therapy

Overview

Biological Basis of NfL as a Therapeutic Target

Neurofilament Structure and Function

Why NfL Is an Ideal Biomarker

NfL in Specific Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Parkinson's Disease and Atypical Parkinsonism

Multiple Sclerosis

Implementation of NfL-Guided Therapy

Clinical Workflow

Step 1: Baseline Assessment

Step 2: Monitoring Protocol

Step 3: Interpretation and Action

Dosing Adjustments Based on NfL

Clinical Integration

NfL in Clinical Trials

Enrichment Strategies

Outcome Measures

Challenges and Limitations

Evidence Summary

Key Publications

Cross-Links to Related Content

Related Pages

Related Mechanisms

Current Status and Future Directions

Clinical Implementation Status

Future Developments

Implementation Recommendations

Conclusion

Comparison with Other Neurodegenerative Biomarkers

NfL vs. Amyloid and Tau Biomarkers

NfL vs. Clinical Outcome Measures

Technical Aspects of NfL Measurement

Assay Platforms

Single Molecule Array (Simoa)

Electrochemiluminescence (ECL)

Other Platforms

Pre-analytical Considerations

Blood Collection

CSF Collection

Reference Values

Economic Considerations

Cost-Effectiveness

Testing Costs

Regulatory Landscape

Current Status

Biomarker Qualification Efforts

Case Studies

Case 1: ALS Treatment Monitoring

Case 2: Alzheimer's Disease Treatment Decision

Case 3: MS Treatment Optimization

Practical Implementation Checklist

For Clinicians

For Healthcare Systems

For Researchers

Conclusion

References

See Also

Related Hypotheses

💬 Discussion